Mark Keibler

Mark Keibler is a highly experienced scientist specializing in metabolomics and drug discovery, currently serving as Senior Scientist at Alnylam Pharmaceuticals since November 2020. Previously, Mark held roles including Senior Scientist in bioprocessing at Ring Therapeutics and Scientist I at Indigo, where practical skills in analytical technologies and process development were cultivated. Mark's prior experience at AbbVie involved senior responsibilities in cell culture process development, including significant contributions to regulatory approvals for novel monoclonal antibodies. With a solid academic foundation, Mark earned a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, following a Bachelor's degree in Chemical and Biomolecular Engineering and Chemistry from the University of Maryland.